Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR)Pre-treatment non-target lung FDG-PET uptake predicts radiation pneumonitis after SABR

Aadel A. Chaudhuri, Michael S. Binkley, Joseph Rigdon, Justin N. Carter, Sonya Aggarwal, Sara A. Dudley, Yushen Qian, Kiran A. Kumar, Wendy Y. Hara, Michael Gensheimer, Viswam S. Nair, Peter G. Maxim, David B. Shultz, Karl Bush, Nicholas Trakul, Quynh Thu Le, Maximilian Diehn, Billy W. Loo, Haiwei Henry Guo

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose To determine if pre-treatment non-target lung FDG-PET uptake predicts for symptomatic radiation pneumonitis (RP) following lung stereotactic ablative radiotherapy (SABR). Methods We reviewed a 258 patient database from our institution to identify 28 patients who experienced symptomatic (grade ⩾ 2) RP after SABR, and compared them to 57 controls who did not develop symptomatic RP. We compared clinical, dosimetric and functional imaging characteristics between the 2 cohorts including pre-treatment non-target lung FDG-PET uptake. Results Median follow-up time was 26.9 months. Patients who experienced symptomatic RP had significantly higher non-target lung FDG-PET uptake as measured by mean SUV (p < 0.0001) than controls. ROC analysis for symptomatic RP revealed area under the curve (AUC) of 0.74, with sensitivity 82.1% and specificity 57.9% with cutoff mean non-target lung SUV > 0.56. Predictive value increased (AUC of 0.82) when mean non-target lung SUV was combined with mean lung dose (MLD). We developed a 0–2 point model using these 2 variables, 1 point each for SUV > 0.56 or MLD > 5.88 Gy equivalent dose in 2 Gy per fraction (EQD2), predictive for symptomatic RP in our cohort with hazard ratio 10.01 for score 2 versus 0 (p < 0.001). Conclusions Patients with elevated pre-SABR non-target lung FDG-PET uptake are at increased risk of symptomatic RP after lung SABR. Our predictive model suggests patients with mean non-target lung SUV > 0.56 and MLD > 5.88 Gy EQD2 are at highest risk. Our predictive model should be validated in an external cohort before clinical implementation.

Original languageEnglish (US)
Pages (from-to)454-460
Number of pages7
JournalRadiotherapy and Oncology
Volume119
Issue number3
DOIs
StatePublished - Jun 1 2016
Externally publishedYes

Fingerprint

Radiation Pneumonitis
Radiotherapy
Lung
Therapeutics
Area Under Curve
Databases

Keywords

  • Fluorodeoxyglucose positron emission tomography (FDG-PET)
  • Lung cancer
  • Mean lung dose
  • Mean non-target lung SUV
  • Radiation pneumonitis
  • Stereotactic ablative radiotherapy (SABR)

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR)Pre-treatment non-target lung FDG-PET uptake predicts radiation pneumonitis after SABR. / Chaudhuri, Aadel A.; Binkley, Michael S.; Rigdon, Joseph; Carter, Justin N.; Aggarwal, Sonya; Dudley, Sara A.; Qian, Yushen; Kumar, Kiran A.; Hara, Wendy Y.; Gensheimer, Michael; Nair, Viswam S.; Maxim, Peter G.; Shultz, David B.; Bush, Karl; Trakul, Nicholas; Le, Quynh Thu; Diehn, Maximilian; Loo, Billy W.; Guo, Haiwei Henry.

In: Radiotherapy and Oncology, Vol. 119, No. 3, 01.06.2016, p. 454-460.

Research output: Contribution to journalArticle

Chaudhuri, AA, Binkley, MS, Rigdon, J, Carter, JN, Aggarwal, S, Dudley, SA, Qian, Y, Kumar, KA, Hara, WY, Gensheimer, M, Nair, VS, Maxim, PG, Shultz, DB, Bush, K, Trakul, N, Le, QT, Diehn, M, Loo, BW & Guo, HH 2016, 'Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR)Pre-treatment non-target lung FDG-PET uptake predicts radiation pneumonitis after SABR', Radiotherapy and Oncology, vol. 119, no. 3, pp. 454-460. https://doi.org/10.1016/j.radonc.2016.05.007
Chaudhuri, Aadel A. ; Binkley, Michael S. ; Rigdon, Joseph ; Carter, Justin N. ; Aggarwal, Sonya ; Dudley, Sara A. ; Qian, Yushen ; Kumar, Kiran A. ; Hara, Wendy Y. ; Gensheimer, Michael ; Nair, Viswam S. ; Maxim, Peter G. ; Shultz, David B. ; Bush, Karl ; Trakul, Nicholas ; Le, Quynh Thu ; Diehn, Maximilian ; Loo, Billy W. ; Guo, Haiwei Henry. / Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR)Pre-treatment non-target lung FDG-PET uptake predicts radiation pneumonitis after SABR. In: Radiotherapy and Oncology. 2016 ; Vol. 119, No. 3. pp. 454-460.
@article{44684bdfd060486da3ecdca96383d0dd,
title = "Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR)Pre-treatment non-target lung FDG-PET uptake predicts radiation pneumonitis after SABR",
abstract = "Purpose To determine if pre-treatment non-target lung FDG-PET uptake predicts for symptomatic radiation pneumonitis (RP) following lung stereotactic ablative radiotherapy (SABR). Methods We reviewed a 258 patient database from our institution to identify 28 patients who experienced symptomatic (grade ⩾ 2) RP after SABR, and compared them to 57 controls who did not develop symptomatic RP. We compared clinical, dosimetric and functional imaging characteristics between the 2 cohorts including pre-treatment non-target lung FDG-PET uptake. Results Median follow-up time was 26.9 months. Patients who experienced symptomatic RP had significantly higher non-target lung FDG-PET uptake as measured by mean SUV (p < 0.0001) than controls. ROC analysis for symptomatic RP revealed area under the curve (AUC) of 0.74, with sensitivity 82.1{\%} and specificity 57.9{\%} with cutoff mean non-target lung SUV > 0.56. Predictive value increased (AUC of 0.82) when mean non-target lung SUV was combined with mean lung dose (MLD). We developed a 0–2 point model using these 2 variables, 1 point each for SUV > 0.56 or MLD > 5.88 Gy equivalent dose in 2 Gy per fraction (EQD2), predictive for symptomatic RP in our cohort with hazard ratio 10.01 for score 2 versus 0 (p < 0.001). Conclusions Patients with elevated pre-SABR non-target lung FDG-PET uptake are at increased risk of symptomatic RP after lung SABR. Our predictive model suggests patients with mean non-target lung SUV > 0.56 and MLD > 5.88 Gy EQD2 are at highest risk. Our predictive model should be validated in an external cohort before clinical implementation.",
keywords = "Fluorodeoxyglucose positron emission tomography (FDG-PET), Lung cancer, Mean lung dose, Mean non-target lung SUV, Radiation pneumonitis, Stereotactic ablative radiotherapy (SABR)",
author = "Chaudhuri, {Aadel A.} and Binkley, {Michael S.} and Joseph Rigdon and Carter, {Justin N.} and Sonya Aggarwal and Dudley, {Sara A.} and Yushen Qian and Kumar, {Kiran A.} and Hara, {Wendy Y.} and Michael Gensheimer and Nair, {Viswam S.} and Maxim, {Peter G.} and Shultz, {David B.} and Karl Bush and Nicholas Trakul and Le, {Quynh Thu} and Maximilian Diehn and Loo, {Billy W.} and Guo, {Haiwei Henry}",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.radonc.2016.05.007",
language = "English (US)",
volume = "119",
pages = "454--460",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR)Pre-treatment non-target lung FDG-PET uptake predicts radiation pneumonitis after SABR

AU - Chaudhuri, Aadel A.

AU - Binkley, Michael S.

AU - Rigdon, Joseph

AU - Carter, Justin N.

AU - Aggarwal, Sonya

AU - Dudley, Sara A.

AU - Qian, Yushen

AU - Kumar, Kiran A.

AU - Hara, Wendy Y.

AU - Gensheimer, Michael

AU - Nair, Viswam S.

AU - Maxim, Peter G.

AU - Shultz, David B.

AU - Bush, Karl

AU - Trakul, Nicholas

AU - Le, Quynh Thu

AU - Diehn, Maximilian

AU - Loo, Billy W.

AU - Guo, Haiwei Henry

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Purpose To determine if pre-treatment non-target lung FDG-PET uptake predicts for symptomatic radiation pneumonitis (RP) following lung stereotactic ablative radiotherapy (SABR). Methods We reviewed a 258 patient database from our institution to identify 28 patients who experienced symptomatic (grade ⩾ 2) RP after SABR, and compared them to 57 controls who did not develop symptomatic RP. We compared clinical, dosimetric and functional imaging characteristics between the 2 cohorts including pre-treatment non-target lung FDG-PET uptake. Results Median follow-up time was 26.9 months. Patients who experienced symptomatic RP had significantly higher non-target lung FDG-PET uptake as measured by mean SUV (p < 0.0001) than controls. ROC analysis for symptomatic RP revealed area under the curve (AUC) of 0.74, with sensitivity 82.1% and specificity 57.9% with cutoff mean non-target lung SUV > 0.56. Predictive value increased (AUC of 0.82) when mean non-target lung SUV was combined with mean lung dose (MLD). We developed a 0–2 point model using these 2 variables, 1 point each for SUV > 0.56 or MLD > 5.88 Gy equivalent dose in 2 Gy per fraction (EQD2), predictive for symptomatic RP in our cohort with hazard ratio 10.01 for score 2 versus 0 (p < 0.001). Conclusions Patients with elevated pre-SABR non-target lung FDG-PET uptake are at increased risk of symptomatic RP after lung SABR. Our predictive model suggests patients with mean non-target lung SUV > 0.56 and MLD > 5.88 Gy EQD2 are at highest risk. Our predictive model should be validated in an external cohort before clinical implementation.

AB - Purpose To determine if pre-treatment non-target lung FDG-PET uptake predicts for symptomatic radiation pneumonitis (RP) following lung stereotactic ablative radiotherapy (SABR). Methods We reviewed a 258 patient database from our institution to identify 28 patients who experienced symptomatic (grade ⩾ 2) RP after SABR, and compared them to 57 controls who did not develop symptomatic RP. We compared clinical, dosimetric and functional imaging characteristics between the 2 cohorts including pre-treatment non-target lung FDG-PET uptake. Results Median follow-up time was 26.9 months. Patients who experienced symptomatic RP had significantly higher non-target lung FDG-PET uptake as measured by mean SUV (p < 0.0001) than controls. ROC analysis for symptomatic RP revealed area under the curve (AUC) of 0.74, with sensitivity 82.1% and specificity 57.9% with cutoff mean non-target lung SUV > 0.56. Predictive value increased (AUC of 0.82) when mean non-target lung SUV was combined with mean lung dose (MLD). We developed a 0–2 point model using these 2 variables, 1 point each for SUV > 0.56 or MLD > 5.88 Gy equivalent dose in 2 Gy per fraction (EQD2), predictive for symptomatic RP in our cohort with hazard ratio 10.01 for score 2 versus 0 (p < 0.001). Conclusions Patients with elevated pre-SABR non-target lung FDG-PET uptake are at increased risk of symptomatic RP after lung SABR. Our predictive model suggests patients with mean non-target lung SUV > 0.56 and MLD > 5.88 Gy EQD2 are at highest risk. Our predictive model should be validated in an external cohort before clinical implementation.

KW - Fluorodeoxyglucose positron emission tomography (FDG-PET)

KW - Lung cancer

KW - Mean lung dose

KW - Mean non-target lung SUV

KW - Radiation pneumonitis

KW - Stereotactic ablative radiotherapy (SABR)

UR - http://www.scopus.com/inward/record.url?scp=84971616757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971616757&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2016.05.007

DO - 10.1016/j.radonc.2016.05.007

M3 - Article

C2 - 27267049

AN - SCOPUS:84971616757

VL - 119

SP - 454

EP - 460

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 3

ER -